Epidemiology and clinical implications of carbapenemase-producing bacteria in Switzerland;Carbapénémases: Implications cliniques et épidémiologiques pour la Suisse

Revue Medicale Suisse

Volumn 8, Issue 338, 2012, Pages 882-889

  Abbas, M ^a   Cherkaoui, A ^b   Fankhauser, C ^c   Schrenzel, J ^b   Harbarth, S ^c  

^a SERVICE DE MÉDECINE INTERNE GÉNÉRALE   (Switzerland)

^b HUG   (Switzerland)

^c Réhabilitation et de Gériatrie HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; BACTERIAL PROTEIN; BETA LACTAMASE;

ARTICLE; BACTERIAL INFECTION; ENTEROBACTERIACEAE; EPIDEMIC; HOSPITAL PATIENT; HUMAN; INFECTION CONTROL; LABORATORY; MORTALITY; SWITZERLAND; ADULT; BIOLOGICAL MODEL; CASE REPORT; COMMUNICABLE DISEASE; DISEASE TRANSMISSION; ENTEROBACTERIACEAE INFECTION; FEMALE; GENETICS; INDIA; MALE; METABOLISM; MULTIDRUG RESISTANCE; PAKISTAN; PATHOGENICITY; PATIENT TRANSPORT; PHYSIOLOGY; PROGNOSIS; REVIEW; TRAVEL;

ADULT; BACTERIAL PROTEINS; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INDIA; MALE; MODELS, BIOLOGICAL; PAKISTAN; PATIENT TRANSFER; PROGNOSIS; SWITZERLAND; TRAVEL;

EID: 84862729131     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lew D, Calandra T. Superbugs from elsewhere. Rev Med Suisse 2011;7:883-4.
2. **Grall N, Andremont A, Armand-Lefèvre L. Résis tance aux carbapénèmes : vers une nouvelle impasse ? Journal des Anti-infectieux 2011;13:87-102.
3. *Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant enterobacteriaceae : Epidemiology and prevention. Clin Infect Dis 2011;53:60-7.
4. Fankhauser C, Cherkaoui A, Renzi G, et al. Carbapenem-resistant enterobacteriacae : A challenge for early detection and infection control. BMC Proceedings 2011;5(Suppl. 6):142.
5. Vora S, Auckenthaler R. What is the significance of extended spectrum betalactamases in clinical practice ? Rev Med Suisse 2009;5:1991-4.
6. Levy SB, Marshall B. Antibacterial resistance worldwide : Causes, challenges and responses. Nature Med 2004;10:S122-9. (Pubitemid 40018235)
7. Giske CG, Sundsfjord AS, Kahlmeter G, et al. Redefining extended-spectrum beta-lactamases : Balancing science and clinical need. J antimicrob Chemother 2009;63:1-4.
8. Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol 2010;300:371-9.
9. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance : A cross-national database study. Lancet 2005;365:579-87. (Pubitemid 40247914)
10. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli. Clin Infect Dis 2001;33:1462-8. (Pubitemid 34246137)
11. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases : The quiet before the storm ? Clin Microbiol Rev 2005;18:306-25.
12. Queenan AM, Bush K. Carbapenemases : The versatile beta-lactamases. Clin Microbiol Rev 2007;20:440-58.
13. Hindiyeh M, Smollen G, Grossman Z, et al. Rapid detection of blaKPC carbapenemase genes by real-time PCR. J Clin Microbiol 2008;46:2879-83.
14. *Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-36.
15. *Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis 2011;53:49-56.
16. Giakkoupi P, Papagiannitsis CC, Miriagou V, et al. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-10). Jv Antimicrob Chemother 2001;66:1510-3.
17. WendtC, Schütt S, Dalpke AH, et al. First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany. Eur J Clin Microbiol Infect Dis 2010;29:563-70.
18. **Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8.
19. Potron A, Poirel L, Nordmann P. Plasmid-mediated transfer of the blaNDM-1 gene in Gram-negative rods. FEMS Microbiol Lett 2011;324:111-6.
20. *Bilavsky E, Schwaber MJ, Carmeli Y. How to stem the tide of carbapenemase-producing enterobacteriaceae ? Proactive versus reactive strategies. Curr Opin Infect Dis 2010;23:327-31.
21. Cohen Stuart J, Leverstein-Van Hall MA. Guideline for phenotypic screening and confirmation of carbapenemases in Enterobacteriaceae. Int J Antimicrob Agents 2010;36:205-10.
22. **Carmeli Y, Akova M, Cornaglia G, et al. Controlling the spread of carbapenemase-producing Gramnegatives : Therapeutic approach and infection control. Clin Microbiol Infect 2010;16:102-11.
23. *Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52:848-55.
24. Wernli D, Haustein T, Conly J, et al. A call for action : The application of the International health regulations to the global threat of antimicrobial resistance. PLoS Med 2011;8:e1001022.
25. Stewardson AJ, Huttner B, Harbarth S. At least it won't hurt : The personal risks of antibiotic exposure. Curr Opin Pharmacol 2011;11:446-52.
26. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297-300.
27. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin : Use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77. (Pubitemid 351589875)
28. Anthony KB, Fishman N, Linkin D, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70. (Pubitemid 351263497)
29. Adler A, Carmeli Y. Dissemination of the Klebsiella pneumoniae carbapenemase in the health care settings : Tracking the trails of an elusive offender. MBio 2011;2:e00280-11.